Picard Medical / SynCardia COO to Deliver Keynote at Venture Café Phoenix During Arizona Tech Week
MWN-AI** Summary
Matt Schuster, the Chief Operating Officer of Picard Medical, will deliver a compelling keynote address at Venture Café Phoenix during Arizona Tech Week, happening on April 9, 2026. This event is a significant gathering spot for innovators and industry leaders focused on Arizona's technology ecosystem. Schuster's presentation will delve into the transformative impact of artificial heart technology, particularly addressing advanced heart failure treatment gaps experienced by underserved patient populations, notably women.
Picard Medical is the parent company of SynCardia Systems, which is renowned for creating the first total artificial heart approved by both the U.S. FDA and Health Canada. Schuster aims to highlight how next-generation, fully implantable total artificial heart systems not only improve patient mobility and quality of life but also enhance treatment eligibility, addressing the gender disparity in mechanical circulatory support. His discussion will draw on recent clinical experiences from leading institutions, including the University of California, San Francisco.
Arizona Tech Week serves as a broader platform that emphasizes collaboration, innovation, and the showcasing of emerging technologies across various sectors, including healthcare and artificial intelligence. The Venture Café event is part of this initiative and features the FemTech AZ Pitch Competition, focusing on women's health innovation.
Schuster emphasized Picard Medical's commitment to fostering medical advancements and clinical collaboration, affirming that events like Venture Café Phoenix are crucial for bridging innovation with real-world healthcare needs. The keynote aims to not only spotlight the advancements in heart technology but also advocate for increased access to life-saving therapies for all patients, particularly women facing advanced heart failure.
For more information on Picard Medical and SynCardia's groundbreaking work, visit www.picardmedical.com or review their SEC filings.
MWN-AI** Analysis
As Picard Medical, Inc. (NYSE American: PMI) prepares for the keynote address by COO Matt Schuster at Venture Café Phoenix during Arizona Tech Week, investors should closely monitor the implications of this event for the company's market positioning and growth potential. Schuster's focus on innovation in artificial heart technology, particularly the accessibility for women with advanced heart failure, may signal a strategic emphasis on expanding the target demographic, thereby enhancing market demand.
Picard Medical, as the leader in total artificial heart technology, stands out in a competitive landscape where the healthcare sector increasingly prioritizes inclusivity. This approach not only aligns with current healthcare trends but can also enhance Picard's reputation and broaden its patient base. The emphasis on women—a demographic historically underrepresented in clinical treatments—could open doors to new partnerships and funding opportunities, particularly in the evolving FemTech sector.
Furthermore, the location of the event at the Phoenix Bioscience Core, a hub for health innovation and collaboration, underscores the strategic importance of networking and synergies with other pioneering entities. Participation in events like the Arizona Tech Week fosters relationships that may lead to favorable contracts or joint ventures, enhancing prospects for growth.
Investors should also pay attention to recent clinical applications of the SynCardia Total Artificial Heart, notably its positive reception among leading hospitals, which boosts credibility. Strong clinical performance further solidifies the company’s market position, making it an attractive option for investors seeking opportunities within the biotechnology arena.
In summary, with its commitment to addressing critical healthcare disparities and the strategic delivery of innovative technologies, Picard Medical exhibits significant growth potential. Investors should consider this moment as a pivotal point for the company's visibility and impact in the healthcare landscape, potentially shaping its trajectory in the years to come.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
– Keynote to highlight innovation in artificial heart technology and expanding access for women with advanced heart failure –
TUCSON, Ariz., April 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Chief Operating Officer Matt Schuster will deliver a keynote address at Venture Café Phoenix during Arizona Tech Week, an event that brings together founders, investors, and innovators to showcase Arizona’s growing technology ecosystem.
Information for Keynote Address at Venture Café Phoenix
Location: Phoenix Bioscience Core at the Center for Entrepreneurial Innovation (CEI) Main Stage located 850 N 5th Street, Phoenix, AZ.
Date and time: Thursday April 9, 2026, from 6:20 p.m. to 6:40 p.m.
Register at:
https://community.venturecafephoenix.org/events/6875508c-69d8-4945-b5ce-6a540e006b7b.
Mr. Schuster’s keynote will focus on the evolving role of artificial heart technology in addressing critical gaps in the treatment of advanced heart failure, particularly among underserved patient populations. His presentation will address how next generation, fully implantable total artificial heart systems may expand access to life sustaining therapy, improve mobility and quality of life, and broaden eligibility for treatment, including for women, who remain underrepresented in mechanical circulatory support.
The broader program will run from 4:30 p.m. to 7:00 p.m. and will include the FemTech AZ Pitch Competition and an International Innovation Mixer focused on women’s health innovation and cross border collaboration.
“Picard Medical’s / SynCardia’s participation in AZ Tech Week reflects the Company’s commitment to advancing next-generation medical technologies through innovation and clinical collaboration and events like Venture Café Phoenix provide an important platform to connect innovation with real world patient needs,” said Matt Schuster, Chief Operating Officer of Picard Medical. “As we continue to advance artificial heart technology, we remain focused on expanding access to therapy and addressing longstanding gaps in care, including those that affect women with advanced heart failure.”
The presentation will also highlight recent clinical experience with the SynCardia Total Artificial Heart at leading transplant centers, including the University of California, San Francisco, where cardiac surgeon Dr. Amy Fiedler and her team have recently implanted the SynCardia Total Artificial Heart in multiple patients as part of advanced heart failure care.
About Arizona Tech Week
Arizona Tech Week is a statewide innovation conference that convenes founders, investors, researchers, and industry leaders through a series of events held across Arizona. The program highlights emerging technologies, entrepreneurship, and collaboration across sectors including life sciences, healthcare, artificial intelligence, and advanced manufacturing. Events such as the Venture Café Phoenix Thursday Gathering provide a platform for innovators and companies to showcase new technologies, exchange ideas, and strengthen Arizona’s rapidly growing innovation ecosystem.
About the Phoenix Bioscience Core and Venture Café Phoenix
The Phoenix Bioscience Core (PBC) is a 30-acre life sciences innovation district located in downtown Phoenix that brings together leading academic institutions including Arizona State University, Northern Arizona University, and the University of Arizona, alongside research organizations such as the Translational Genomics Research Institute, part of City of Hope, and the International Genomics Consortium. The district also collaborates closely with major healthcare systems including Banner Health, Phoenix Children’s, Dignity Health, HonorHealth, the Phoenix VA, and Valleywise Health, creating a hub for biomedical research, clinical innovation, and technology development.
Venture Café Phoenix hosts its flagship “Thursday Gathering” at 850 N 5th Street, bringing together entrepreneurs, investors, researchers, and industry leaders each week to exchange ideas and build connections. Held every Thursday from 4:30 pm to 7:00 pm, the gathering attracts more than 150 participants and features breakout sessions, mentor hours, demonstrations, and community programming designed to foster collaboration and strengthen Arizona’s innovation ecosystem.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
FAQ**
How does Picard Medical Inc. PMI plan to leverage the advancements in artificial heart technology to specifically address the unique needs of women with advanced heart failure?
What collaborative initiatives is Picard Medical Inc. PMI pursuing at Arizona Tech Week to enhance the treatment landscape for underserved patient populations suffering from heart failure?
In what ways does the SynCardia Total Artificial Heart's clinical experience at leading transplant centers inform Picard Medical Inc. PMI's future innovations and patient accessibility efforts?
How does Picard Medical Inc. PMI envision the impact of next-generation artificial heart systems on improving overall mobility and quality of life for patients living with advanced heart failure?
**MWN-AI FAQ is based on asking OpenAI questions about Picard Medical Inc. (NYSE: PMI).
NASDAQ: PMI
PMI Trading
16.83% G/L:
$0.5025 Last:
22,005,914 Volume:
$0.462 Open:
